Skip to main content
SpringerLink
Log in

Liver Metastases of Neuroendocrine Tumors Rarely Show Overlapping Immunoprofile with Hepatocellular Carcinomas

  • Published:
Endocrine Pathology Aims and scope Submit manuscript

Abstract

The distinction of hepatocellular carcinoma (HCC), neuroendocrine tumor (NET) metastatic to the liver, and cholangiocarcinoma (CC) can sometimes be challenging on small biopsies. Tissue microarrays were constructed from HCCs, NETs, and CCs. The immunoprofile was evaluated using HepPar1, glypican-3 (GPC3), synaptophysin (SYN), chromogranin A (CHR), CD56, MOC-31, and pCEA. One hundred thirteen HCCs, 48 NETs, and 44 CCs were included. Of HCCs, 107 (95 %) expressed HepPar1 and/or GPC3, 52 (46 %) both, and 97 (88 %) marked with pCEA (canalicular pattern). Seven (6 %) expressed CD56, of which 3 (3 %) expressed SYN. All 7 HCCs that expressed CD56 and/or SYN also expressed HepPar1 and/or GPC3, and none of the HCCs expressed CHR. Fourteen (13 %) expressed MOC-31. All 48 NETs expressed at least one neuroendocrine marker: 47 (98 %) positive for SYN, 40 (83 %) for CHR, 39 (81 %) for CD56, and 34 (71 %) for all three markers. None expressed HepPar1 or GPC3. All 44 CCs showed at least focal reactivity with MOC-31 and pCEA (membranous/cytoplasmic). One (2 %) was positive for HepPar1, 4 (9 %) for GPC3, 1 (2 %) for SYN and CHR, and 7 (16 %) for CD56. HCCs rarely express CD56 and SYN, while all express either HepPar1 or GPC3. NETs do not express HepPar1 or GPC3 and almost always express SYN, while CHR and CD56 are seen in most cases. Rare CCs focally express HepPar1 and GPC3. Utilizing a limited staining panel can efficiently distinguish HCCs, NETs, and CCs and help avoid diagnostic pitfalls on small biopsies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Al-Muhannadi N, Ansari N, Brahmi U, Satir AA: Differential diagnosis of malignant epithelial tumours in the liver: an immunohistochemical study on liver biopsy material. Ann Hepatol, 10(4):508–515,2011.

    PubMed  Google Scholar 

  2. Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA: Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg, 187(1):88–92,1998

    Article  CAS  PubMed  Google Scholar 

  3. Arista-Nasr J, Fernandez-Amador JA, Martinez-Benitez B, de Anda-Gonzalez J, Bornstein-Quevedo L: Neuroendocrine metastatic tumors of the liver resembling hepatocellular carcinoma. Ann Hepatol, 9(2):186–191,2010.

    PubMed  Google Scholar 

  4. Chu PG, Ishizawa S, Wu E, Weiss LM: Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein. Am J Surg Pathol, 26(8):978–988, 2002.

    Article  PubMed  Google Scholar 

  5. Wennerberg AE, Nalesnik MA, Coleman WB: Hepatocyte paraffin 1: a monoclonal antibody that reacts with hepatocytes and can be used for differential diagnosis of hepatic tumors. Am J Pathol, 143(4):1050–1054, 1993.

    CAS  PubMed  PubMed Central  Google Scholar 

  6. Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, Niki T, Shibahara J, Mori M, Makuuchi M et al.: The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol, 18(12):1591–1598, 2005.

    CAS  PubMed  Google Scholar 

  7. Fan Z, van de Rijn M, Montgomery K, Rouse RV: Hep par 1 antibody stain for the differential diagnosis of hepatocellular carcinoma: 676 tumors tested using tissue microarrays and conventional tissue sections. Mod Pathol, 16(2):137–144, 2003.

    Article  PubMed  Google Scholar 

  8. Libbrecht L, Severi T, Cassiman D, Vander Borght S, Pirenne J, Nevens F, Verslype C, van Pelt J, Roskams T: Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules. Am J Surg Pathol, 30(11):1405–1411, 2006.

    Article  PubMed  Google Scholar 

  9. Wang XY, Degos F, Dubois S, Tessiore S, Allegretta M, Guttmann RD, Jothy S, Belghiti J, Bedossa P, Paradis V: Glypican-3 expression in hepatocellular tumors: diagnostic value for preneoplastic lesions and hepatocellular carcinomas. Hum Pathol, 37(11):1435–1441, 2006.

    Article  CAS  PubMed  Google Scholar 

  10. Coston WM, Loera S, Lau SK, Ishizawa S, Jiang Z, Wu CL, Yen Y, Weiss LM, Chu PG: Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry. Am J Surg Pathol, 32(3):433–444, 2008.

    Article  PubMed  Google Scholar 

  11. Shafizadeh N, Ferrell LD, Kakar S: Utility and limitations of glypican-3 expression for the diagnosis of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol, 21(8):1011–1018, 2008.

    Article  CAS  PubMed  Google Scholar 

  12. Yan B, Wei JJ, Qian YM, Zhao XL, Zhang WW, Xu AM, Zhang SH: Expression and clinicopathologic significance of glypican 3 in hepatocellular carcinoma. Ann Diagn Pathol, 15(3):162–169, 2011.

    Article  PubMed  Google Scholar 

  13. Machinami R, Oono Y: Carcinoembryonic antigen and lectin binding in the bile canalicular structures of hepatocellular carcinoma. Virchows Arch A Pathol Anat Histopathol, 412(2):111–118, 1987.

    Article  CAS  PubMed  Google Scholar 

  14. Morrison C, Marsh W, Jr., Frankel WL: A comparison of CD10 to pCEA, MOC-31, and hepatocyte for the distinction of malignant tumors in the liver. Mod Pathol, 15(12):1279–1287, 2002.

    Article  PubMed  Google Scholar 

  15. Kakar S, Gown AM, Goodman ZD, Ferrell LD: Best practices in diagnostic immunohistochemistry: hepatocellular carcinoma versus metastatic neoplasms. Arch Pathol Lab Med, 131(11):1648–1654, 2007.

    PubMed  Google Scholar 

  16. Wang JH, Dhillon AP, Sankey EA, Wightman AK, Lewin JF, Scheuer PJ: 'Neuroendocrine' differentiation in primary neoplasms of the liver. J Pathol, 163(1):61–67, 1991.

    Article  CAS  PubMed  Google Scholar 

  17. Garcia de Davila MT, Gonzalez-Crussi F, Mangkornkanok M: Fibrolamellar carcinoma of the liver in a child: ultrastructural and immunohistologic aspects. Pediatr Pathol, 7(3):319–331, 1987.

  18. Gornicka B, Ziarkiewicz-Wroblewska B, Wroblewski T, Wilczynski GM, Koperski L, Krawczyk M, Wasiutynski A: Carcinoma, a fibrolamellar variant--immunohistochemical analysis of 4 cases. Hepatogastroenterology, 52(62):519–523, 2005.

    PubMed  Google Scholar 

  19. Ward SC, Huang J, Tickoo SK, Thung SN, Ladanyi M, Klimstra DS: Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation. Mod Pathol, 23(9):1180–1190, 2010.

    Article  CAS  PubMed  Google Scholar 

  20. Mounajjed T, Zhang L, Wu TT: Glypican-3 expression in gastrointestinal and pancreatic epithelial neoplasms. Hum Pathol, 44(4):542–550; 2013.

    Article  CAS  PubMed  Google Scholar 

  21. Porcell AI, De Young BR, Proca DM, Frankel WL: Immunohistochemical analysis of hepatocellular and adenocarcinoma in the liver: MOC31 compares favorably with other putative markers. Mod Pathol, 13(7):773–778, 2000.

    Article  CAS  PubMed  Google Scholar 

  22. Roskams T, van den Oord JJ, De Vos R, Desmet VJ: Neuroendocrine features of reactive bile ductules in cholestatic liver disease. Am J Pathol, 137(5):1019–1025, 1990.

    CAS  PubMed  PubMed Central  Google Scholar 

  23. Akiba J1, Nakashima O, Hattori S, Tanikawa K, Takenaka M, Nakayama M, Kondo R, Nomura Y, Koura K, Ueda K, Sanada S, Naito Y, Yamaguchi R, Yano H. Clinicopathologic analysis of combined hepatocellular-cholangiocarcinoma according to the latest WHO classification. Am J Surg Pathol. 37(4):496–505, 2013.

  24. Ikeda H, Sato Y, Yoneda N, Harada K, Sasaki M, Kitamura S, Sudo Y, Ooi A, Nakanuma Y: alpha-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression. Hum Pathol, 43(11):1955–1963, 2012.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, The Ohio State University Wexner Medical Center, 129 Hamilton Hall, Columbus, OH, 43210, USA

    Ming Jin, Xiaoping Zhou, Martha Yearsley & Wendy L. Frankel

Authors
  1. Ming Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaoping Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martha Yearsley
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wendy L. Frankel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wendy L. Frankel.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jin, M., Zhou, X., Yearsley, M. et al. Liver Metastases of Neuroendocrine Tumors Rarely Show Overlapping Immunoprofile with Hepatocellular Carcinomas. Endocr Pathol 27, 253–258 (2016). https://doi.org/10.1007/s12022-016-9442-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12022-016-9442-7

Keywords

Search

Navigation